

**Room : Auguste Rodin
Friday 03 December, 2021
15.30-17.30 CET / 09.30 - 11.30 EST**

iCVCT. HEMODYNAMIC SUPPORT DEVICES TRIALS
Chairpersons: Navin Kapur (Boston, USA) & George Dangas (New York, USA)

**Mechanical support devices in shock. A bird's eye view on current data
Temporal and regional trends in mechanical support devices use in shock**

**European Perspective
Alaide Chieffo (Milano, ITA)**

**North American Perspective
Navin Kapur (Boston, USA)**

**Smart machines and machine learning for Hemodynamic Support Devices: Case Example- Impella
Dawn Bardot (AbioMed, USA)**

**Which support device if any should I use in shock? Issues with Current Trial designs
Holger Thiele (Leipzig, GER)**

**Innovative approaches for screening pts with hemodynamic collapse for enrollment in trials
Chuck Simonton (Abiomed, USA)**

**Trials to evaluate use of Hemodynamic support in PCI: PROTECT IV
George Dangas (New York, USA)**

**Door-to-unload trial for anterior STEMI: Challenges in STEMI Trials
Navin Kapur (Boston, USA)**


**MCS in Shock: Current Approved indications and Evidence Gaps
Meir Shinnar (FDA, USA)**

THE iCVCT FORUM Multi-Stakeholder Moderated Debate

TRIALS IN HEMODYNAMIC SUPPORT DEVICES
Chairpersons: Navin Kapur (Boston, USA) & George Dangas (New York, USA)

**Dawn Bardot (AbioMed, USA), Alaide Chieffo (Milano, ITA); George Dangas (New York, USA); Navin Kapur (Boston, USA);
Konstantin Krychtiuk (Durham, USA); Ramesh Mazhari (Washington, USA); Ileana Pina (Detroit, USA), Yves Rosenberg (NIH, USA);
Meir Shinnar (FDA, USA); Chuck Simonton (Abiomed, USA), Holger Thiele (Leipzig, GER), Bram Zuckerman (FDA, USA)**

**Room : Pierre-Auguste Renoir
Saturday 04 December, 2021
13.00-15.00 CET / 07:00 -09:00 EST**



**iCVCT. ANTITHROMBOTIC THERAPY TRIALS. NEW KIDS ON THE BLOCK.
Chairpersons: Michelle O'Donoghue (Boston, USA) & Gabriel Steg (Paris, FRA)**

**What ischemic cost, if any, is tolerable for avoiding bleeding?
Dominick Angiolillo (Miami, USA)**

**Self-administered subcutaneous anti-thrombotic therapy. Opportunities and trial design issues with Selatogrel
Gabriel Steg (Paris, FRA)**

**Pre-hospital anti-thrombotic trials
Arnoud van't Hof (Maastricht, NED)**

**Industry viewpoint
Jack Lawrence (Janssen, USA)
Corine Bernaud (Idorsia, CH), Martin Unverdorben (Daiichi Sankyo, USA), Robert Hillman (Celcor, USA)**

**Regulatory viewpoint
Ellis Unger (Former FDA experience, USA)**

**How different should the anti Xla trials be: Population, endpoints, duration of therapy, disease states?
Michael Gibson (Boston, USA)**

THE iCVCT FORUM Multi-Stakeholder Moderated Debate



**ANTITHROMBOTIC THERAPY TRIALS. NEW KIDS ON THE BLOCK.
Chairpersons: Michelle O'Donoghue (Boston, USA) & Gabriel Steg (Paris, FRA)**

Panelists : Dominick Angiolillo (Miami, USA); Suzanne Baron (Burlington, USA) ; Deepak Bhatt (Boston, USA), Corine Bernaud (Idorsia, CH), George Dargas (New York, USA); Efthymios Deliargyris (Cytosorbents, USA); Michael Gibson (Boston, USA); Robert Hillman (Celcor, USA); Jack Lawrence (Janssen, USA); Victoria Lee (Cytosorbents, USA); Michelle O'Donoghue (Boston, USA), Manesh Patel (Durham, USA), Duane Pinto (Boston, USA); Sébastien Roux (Idorsia, CH); Frank Sellke (Providence, USA); Gabriel Steg (Paris, FRA), Robert Storey (Sheffield, GBR); Ellis Unger (Former FDA experience, USA); Martin Unverdorben (Daiichi Sankyo, USA); Arnoud van't Hof (Maastricht, NED)

**Room : Pierre-Auguste Renoir
Saturday 04 December, 2021
15.30-17.30 CET / 09.30 - 11.30 EST**



**iCVCT. PERIOPERATIVE MANAGEMENT OF ANTITHROMBOTIC THERAPY
Chairpersons: Suzanne Baron (Burlington, USA) & Deepak Bhatt (Boston, USA)**

Perioperative Antiplatelet Therapy Dilemma
Dominick Angiolillo (Miami, USA)

Bridging Antiplatelet Therapy With Cangrelor
George Dangas (New York, USA)

Extracorporeal blood purification from antithrombotic agents: a novel paradigm?
Robert Storey (Sheffield, GBR)

THE iCVCT FORUM Multi-Stakeholder Moderated Debate



**PERIOPERATIVE MANAGEMENT OF ANTITHROMBOTIC THERAPY: IMPLICATIONS FOR TRIAL DESIGNS.
Chairpersons: Suzanne Baron (Burlington, USA) & Deepak Bhatt (Boston, USA)**

Panelists : Dominick Angiolillo (Miami, USA); Suzanne Baron (Burlington, USA) ; Deepak Bhatt (Boston, USA), Corine Bernaud (Idorsia, CH), George Dangas (New York, USA); Efthymios Deliargyris (Cytosorbents, USA); Robert Harrington (Stanford, USA), Jack Lawrence (Janssen, USA), Victoria Lee (Cytosorbents, USA)Michelle O'Donoghue (Boston, USA), Manesh Patel (Durham, USA), Duane Pinto (Boston, USA), Sébastien Roux (Idorsia, CH) ; Frank Sellke (Providence, USA); Gabriel Steg (Paris, FRA), Norman Stockbridge (FDA, USA), Robert Storey (Sheffield, GBR)

**Room : Pierre-Auguste Renoir
Saturday 04 December, 2021
18.00-20.00 CET / 12.00 - 14.30 EST**



iCVCT. TRIALS IN HIGH BLEEDING RISK PATIENTS

Chairperson: Robert Harrington (Stanford, USA) & Frank Sellke (Providence, USA)

PCI device/drug synergy Trials in high-bleeding risk patients
Evolving landscapes in coronary stents for high bleeding risk patients
Stephan Windecker (Bern, CH)

Antiplatelet therapy in high bleeding risk patients: walking a tightrope
Roxana Mehran (New York, USA)

Utility of risk stratification tools in Trials: balancing the ischemic and bleeding risks
Davide Capodanno (Catania, ITA)

Alternative Pathways to reduce Risks: Implications for PCSK9 and Ao A 1 (Human)
John Alexander (Durham, USA)

Alternative Pathways and Future Trial Designs to reduce Risks
Michael Gibson (Boston, USA)

Future trials in high bleeding risk patients: 'speaking the same language':
Regulatory viewpoint
Adrian Magee (FDA, USA)

Industry viewpoint
Sandeep Brar (Medtronic, USA), Victoria Lee (Cytosorbents, USA)

Patient's viewpoint
Robin Martinez (Denver, USA)

THE iCVCT FORUM Multi-Stakeholder Moderated Debate




TRIALS AND HIGH BLEEDING RISK PATIENTS

Chairpersons: Robert Harrington (Stanford, USA) & Frank Sellke (Providence, USA)

Panelists : Alexandre Abizaid (Sao Paulo, BRA); John Alexander (Durham, USA); Dominick Angiolillo (Miami, USA); Sandeep Brar (Medtronic, USA), Davide Capodanno (Catania, ITA), Efthymios Deliargyris (Cytosorbents, USA), Michael Gibson (Boston, USA), Robert Harrington (Stanford, USA); Victoria Lee (Cytosorbents, USA); Renato Lopes (Durham, USA); Adrian Magee (FDA, USA); Robin Martinez (Denver, USA); Roxana Mehran (New York, USA); Duane Pinto (Boston, USA), Frank Sellke (Providence, USA); Stephan Windecker (Bern, CH), Robert Yeh (Boston, USA)

**Room: Edouard Manet
Sunday 05 December, 2021
13.00-15.00 CET / 07:00 -09:00 EST**



iCVCT. REVASCULARIZATION TRIALS
Chairpersons: Donald Cutlip (Boston, USA) & Marie-Claude Morice (Paris, FRA)

Management of left main disease/ MV disease

Coronary imaging for optimal outcomes in left main/MV disease
Akiko Maehara (New York, USA)

Left main revascularization trials: Debate taken from another angle
Frank Sellke (Richmond, USA)


Revascularization trials in patients with diabetes mellitus

Individualizing revascularization approach for patients with DM
David J Cohen (New York, USA)

Industry Viewpoint
Chuck Simonton (Abiomed, USA)

FDA Viewpoint
Adrian Magee (FDA, USA)

THE CVCT FORUM Multi-Stakeholder Moderated Debate



REVASCULARIZATION TRIALS
Chairpersons: Donald Cutlip (Boston, USA) & Marie-Claude Morice (Paris, FRA)

Alexandre Abizaid (Sao Paulo, BRA), Yousif Ahmad (Los Angeles, USA), Dominick Angiolillo (Miami, USA), Julia Baron (Derby, GBR), Robert Byrne (Dublin, IRE); Davide Cao (New York, USA); David J Cohen (New York, USA), Donald Cutlip (Boston, USA), George Dangas (New York, USA), John Gregson (London, USA); Adrian Magee (FDA, USA); Akiko Maehara (New York, USA); Gary Mintz (Washington, USA), Marie-Claude Morice (Paris, FRA); Johnny Nicolas (New York, USA); Frank Sellke (Richmond, USA), Chuck Simonton (Abiomed, USA); Giulio Stefanini (Milano, ITA)

**Room: Edouard Manet
Sunday 05 December, 2021
15.30-17.30 CET / 09.30 - 11.30 EST**



**iCVCT – CSTN joint session. SURGICAL TRIALS IN CARDIOVASCULAR DISEASE
Chairpersons: Patrick O’Gara (New York, USA) & Michael Mack (Dallas, USA)**

**Challenges in Creating a Surgical Trials Network: Setting the Stage
Annetine Gelijns (New York, USA)**

**Designing Trials Comparing Percutaneous vs Open Surgical Procedures: the PRIMARY Trial
Joanna Chikwe (Los Angeles, USA)**

**Designing Clinical Trials using Digital Health Tools
Alexander Iribarne (Lebanon, USA)**

**Choosing between Highly Controlled and Pragmatic Designs
Emilia Bagiella (New York, USA)**

**The Need for Cardiac Surgery Clinical Trials in Women
Mario Gaudino (New York, USA)**

**Reengineering a Surgical Trials Network for a Pandemic
Peter Kent Smith (Durham, USA)**

**Regulatory viewpoint
Bernard Vasseur (FDA, USA)**

THE iCVCT FORUM Multi-Stakeholder Moderated Debate



**SURGICAL TRIALS IN CARDIOVASCULAR DISEASE
Chairpersons: Patrick O’Gara (New York, USA) & Michael Mack (Dallas, USA)**

Panelists: Emilia Bagiella (New York, USA), Christina Eleanor Barkauskas (Durham, USA), Sanjeev Bhavnani (La Jolla, USA), Michael Bowdish (Los Angeles, USA), Joanna Chikwe (Los Angeles, USA), Mario Gaudino (New York, USA), Annetine Gelijns (New York, USA), Alexander Iribarne (Lebanon, USA), Mariell Jessup (AHA, Hingham, USA), Darae Ko (Boston, USA), Martin Leon (New York, USA), Michael Mack (Dallas, USA), Roxana Mehran (New York, USA), Patrick O’Gara (New York, USA), Jessica Overbey (New York, USA), Peter Kent Smith (Durham, USA); Bernard Vasseur (FDA, USA)

**Room: Edouard Manet
Sunday 05 December, 2021
18.00-20.30 CET / 12.00 - 14.30 EST**



iCVCT. MITRAL AND TRICUSPID VALVE TRIALS
Chairpersons: Jeffrey Borer (New York, USA) & Mayra Guerrero (Rochester, USA)

A tale of two trials COAPT and Mitral FR: Lessons learned, future direction
Milton Packer (Dallas, USA)

Trial Design- Will Medical Management of HF impinge on TMVR?
Clyde Yancy (Chicago, USA)

Mitral Valve Academic Research Consortium: Status Update
Saibal Kar (Los Angeles, USA)

Tricuspid Valve Academic Research Consortium: Why now?
Rebecca Hahn (New York, USA)

Trial design issues in Tricuspid valve disease: Patient population, Endpoints
Susheel Kodali (New York, USA)

Clinician Viewpoint
Jamie Mc Cabe (Washington, USA)

FDA viewpoint
ChangFu Wu (FDA, USA)
Nicole Ibrahim (FDA, USA)

Industry View
Dominic Allocco (Boston Scientific, USA)

THE iCVCT FORUM Multi-Stakeholder Moderated Debate



IMPLICATIONS FOR FUTURE DEVICES IN THIS ARENA
Chairpersons: Jeffrey Borer (New York, USA) & Mayra Guerrero (Rochester, USA)

**Panelists: Dominic Allocco (Boston Scientific, USA); Jeffrey Borer (New York, USA); Biykem Bozkurt (Houston, USA);
Alaide Chieffo (Milano, ITA); Victoria Delgado (Leiden, NED); ChangFu Wu (FDA, USA), Rebecca Hahn (New York, USA);
Saibal Kar (Los Angeles, USA); Susheel Kodali (New York, USA), Karl-Patrik Kresoja (Leipzig, GER); Nicole Ibrahim
(FDA, USA); Jamie Mc Cabe (Washington, USA), Mayra Guerrero (Rochester, USA); Milton Packer (Dallas, USA), Anna
Sonia Petronio (Pisa, ITA); Iliana Pina (Detroit, USA), Gilbert Tang (New York, USA); Jaime Wheeler (Edwards, USA);
Clyde Yancy (Chicago, USA), Ori Ben Yehuda (San Diego, USA), Bram Zuckerman (FDA, USA)**